Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector.
about
Adeno-associated virus-mediated cancer gene therapy: current statusLong-term efficacy following readministration of an adeno-associated virus vector in dogs with glycogen storage disease type IaEnhanced efficacy from gene therapy in Pompe disease using coreceptor blockadeKidney-specific expression of GFP by in-utero delivery of pseudotyped adeno-associated virus 9.Preclinical Development of New Therapy for Glycogen Storage Diseases.Large animal models and new therapies for glycogen storage disease.In Vivo Zinc Finger Nuclease-mediated Targeted Integration of a Glucose-6-phosphatase Transgene Promotes Survival in Mice With Glycogen Storage Disease Type IA.Multiple recombinant adeno-associated viral vector serotypes display persistent in vivo gene expression in vector-transduced rat stifle joints.Pathogenesis of growth failure and partial reversal with gene therapy in murine and canine Glycogen Storage Disease type IaThe upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia.Lessons from new mouse models of glycogen storage disease type 1a in relation to the time course and organ specificity of the disease.Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics.Adeno-associated virus gene therapy prevents hepatocellular adenoma in murine model of glycogen storage disease type Ia.In search of proof-of-concept: gene therapy for glycogen storage disease type Ia.Targeted deletion of kidney glucose-6 phosphatase leads to nephropathy.
P2860
Q27026177-15DA629A-45DC-4CBA-AB23-975C63016CB3Q33720634-B706B2D0-F701-41D1-8175-23C92A8FED86Q34999729-E34006B5-58FB-4449-89BB-20242F0BFB34Q35184168-D49863A7-5A13-40D7-81A9-F28DD0F2166DQ35677604-2A04D4CF-49C5-450C-A210-E87962A13BB0Q35886078-953C81F7-71DB-4DEC-913B-C2C747C77E2EQ36951279-014B367C-B38D-4F50-9362-C92BCA8BA0A1Q37066342-301FEF69-234F-49AD-9B7E-EA57DCAF387CQ37150574-37056D20-5100-4AA3-9FC0-851526E3359EQ37503995-48637F04-49FB-4356-9D81-CFAB085657C0Q38244085-07EC3CAE-95A4-4E2E-BD33-E466D528E40DQ38263927-49213626-27E8-4AD0-8C32-C33666A02FCCQ44478940-826EE2CE-3352-4202-96CF-6271D426A05AQ45876893-87CFB2A3-3535-429F-92B1-363E89FE3DDDQ50355525-9F7F6613-E83A-4CE9-B186-796793EEA209
P2860
Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Hepatorenal correction in muri ...... adeno-associated virus vector.
@ast
Hepatorenal correction in muri ...... adeno-associated virus vector.
@en
type
label
Hepatorenal correction in muri ...... adeno-associated virus vector.
@ast
Hepatorenal correction in muri ...... adeno-associated virus vector.
@en
prefLabel
Hepatorenal correction in muri ...... adeno-associated virus vector.
@ast
Hepatorenal correction in muri ...... adeno-associated virus vector.
@en
P2093
P2860
P356
P1433
P1476
Hepatorenal correction in muri ...... adeno-associated virus vector.
@en
P2093
Alex R Kemper
Andrew Bird
Dwight D Koeberl
Gentzon Hall
Michelle P Winn
Peter J Lavin
Songtao Li
Talmage T Brown
Xiaoyan Luo
P2860
P304
P356
10.1038/MT.2011.126
P577
2011-07-05T00:00:00Z